


13 - 16 October, 2026 | Athens, Greece


BIOEMTECH



6th Annual BIOEMTECH Preclinical Workshop

Once per year, at BIOEMTECH, we open our doors to the **Drug Discovery & RadioLigand Therapy** community, creating a space to exchange methodologies, insights and experience. Leading speakers from Academia & Industry come together to explore best practices, combining scientific discussions with hands-on experience in our boutique GLP laboratories.



Companies joining the Workshop



3B Pharmaceuticals



ARTBIO



RAD

RADIOPHARM THERANOSTICS



NAVIGO
PRECISION



Ratio
THERAPEUTICS

TRACER



NANOMAB



United
Theranostics



A warm welcome



6th Annual
BIOEMTECH
Preclinical
Workshop

Welcome to the 6th Annual BIOEMTECH Preclinical Workshop!

After years of active involvement in **Drug Discovery** and **RadioLigand Therapy**, we set out to create a workshop that reflects the challenges, opportunities and questions we encounter throughout our own journey. Inspired by years of participation in scientific meetings around the world, our goal is to bring together researchers and industry professionals in an environment that promotes knowledge exchange, open discussion and networking. The Workshop is designed to provide participants with a **comprehensive view of the radiopharmaceutical development pathway**, from preclinical evaluation to clinical translation, while creating opportunities for new collaborations and professional connections.

Main workshop points:

- From target biology to preclinical RLT package
- Translational planning and product readiness before clinical entry
- Theranostics and early-phase development pathways
- Targeting platforms and combination strategies
- Regulatory readiness and late translational decision-making

The Workshop will begin with a first day dedicated to a visit to our laboratories, offering participants a firsthand look at key preclinical research workflows.

Looking forward to welcoming you in Athens and sharing insightful conversations!

Past attendees have said:

“This has been a great meeting with varied and highly relevant discussions. Thank you to the organisers. I can recommend attendance in future years to others.”

Senior Director Research Strategy
Telix Pharmaceuticals

“Thank you to the BIOEMTECH team for the invitation to such an engaging imaging workshop and panel discussion on radioligand theranostics! I thoroughly enjoyed the diverse conversations on topics ranging from dosimetry, imaging modalities, and animal models to their impact on the design of RLTs. I was particularly impressed with the new imaging facility and capabilities.”

Director Biological Engineer
AstraZeneca

“The workshop was exceptionally well organized, offering high-quality scientific content, practical insights, and valuable networking in a highly collaborative atmosphere. I left with a deeper understanding of several new scientific perspectives. It was a truly enriching experience.”

Head of *in vivo* Research
ARTBIO

Our Speakers & Panelists



6th Annual
BIOEMTECH
Preclinical
Workshop



Jeff Norenberg
Founder, CEO & Chairman
iSeek Biopharma



Vicki Jardine
VP Global Clinical Development
Ratio Therapeutics



Jon Archbold
Associate Director
Translational Imaging
Bayer



Munir Ghesani
Chief Medical Officer
United Theranostics



Michal Zimmermann
Associate Director
In Vitro Target Validation
AstraZeneca



Anneli Savinainen
VP Head of Preclinical
Development
Mariana Oncology
(a Novartis company)



Jon Goodwin
Director, Discovery
ARTBIO



Marion Malenge
Director RLT Discovery &
Preclinical Sciences
Actithera

Our Speakers & Panelists



6th Annual
BIOEMTECH
Preclinical
Workshop



Ina Coburger

Scientist Protein Analytics

Navigo Precision



Hong Hoi Ting

Co-Founder & Non-
Executive Director

NanoMab Technology



Elisa Napoli

Radiopharmaceutical Expert

University of Oslo



Famke van Renesse - Brouwer

Senior Business-to-Science
Manager

TRACER



Jan Lennart von Hacht

Project & Alliance Manager

3B Pharmaceuticals



Levente Meszaros

VP Preclinical &
Translational Sciences

Radiopharm Theranostics

Workshop day 1

Tuesday 13 October



6th Annual
BIOEMTECH
Preclinical
Workshop

09:00 Bus transfer from Central Athens Hotel to BIOEMTECH Laboratories

09:45 - 10:30 Welcome coffee and introductions

BIOEMTECH

10:30

Overview of BIOEMTECH capabilities for preclinical RLT development

10:30 - 13:00 GLP Laboratory visit and demonstrations

A guided visit through BIOEMTECH's preclinical research processes, giving participants firsthand insight into eyes™ imaging systems production facilities, *in vitro* assays, model development, radio-compound preparation, anaesthesia and compound administration procedures, as well as image acquisition and an introduction to imaging workflows.

13:00 - 14:30 Lunch and Networking break

15:00 Bus transfer from BIOEMTECH Laboratories to Central Athens Hotel

20:00 Welcome reception @ Central Hotel Athens rooftop

Workshop day 2

Wednesday 14 October



6th Annual
BIOEMTECH
Preclinical
Workshop

09:00 Registration and welcome coffee

BIOEMTECH

All participants

09:30

Workshop opening & participants roundtable

Session 1: From target biology to preclinical RLT package

Anneli Savinainen

VP Head of Preclinical Development

Mariana Oncology (a Novartis company)

Marion Malenge

Director RLT Discovery & Preclinical Sciences

Actithera

10:10

Preclinical development of a DLL3-targeted radiotherapeutic agent

10:50

Designing and interpreting preclinical biodistribution studies for RLT translation

11:30 - 12:00 Coffee break

Jon Archbold

Associate Director Translational Imaging

Bayer

Moderator: **Marion Malenge**

Participants: **Anneli Savinainen, Jon Archbold**

12:00

Successful outsourcing of preclinical RLT studies

12:40

Panel discussion

Building a robust preclinical RLT package

13:20 - 14:20 Lunch and Networking break

Session 2: Translational planning and product readiness before clinical entry

Elisa Napoli

Radiopharmaceutical Expert

University of Oslo

Jon Goodwin

Director, Discovery

ARTBIO

Famke van Renesse-Brouwer

Senior Business-to-Science Manager

TRACER

Moderator: **Famke van Renesse-Brouwer**

Participants: **Elisa Napoli, Levente Meszaros**

14:20

Development of QC methods for alpha emitting radiopharmaceuticals

15:00

ARTistry platform for alpha RLT development

15:40

From preclinical to clinical: Choosing the right translation strategy for RLTs

16:10

Panel discussion

When is an RLT candidate ready to move toward the clinic?

17:00 - 17:30 Wrap-up & Closing remarks

19:00 Guided visit to the Museum of Cycladic Art followed by dinner

Workshop day 3

Thursday 15 October



6th Annual
BIOEMTECH
Preclinical
Workshop

09:00 Registration and welcome coffee

Session 3: Theranostics and early-phase development pathways

Munir Ghesani

Chief Medical Officer

United Theranostics

09:30

From molecular vision to therapeutic reality: the past, present and future of theranostics

Jan Lennart von Hacht

Project & Alliance Manager

3B Pharmaceuticals

10:10

Peptides in RLT (pre)clinical development

10:50 - 11:20 Coffee break

Levente Meszaros

VP Preclinical & Translational Sciences

Radiopharm Theranostics

11:20

Navigating the preclinical landscape to support early-phase trials in the USA and Australia

Moderator: **Munir Ghesani**

Participants: **Jan Lennart von Hacht, Levente**

Meszaros

12:00

Panel discussion

From molecular design to a development-ready radiopharmaceutical

12:40 - 13:40 Lunch and Networking break

Session 4: Targeting platforms and combination strategies

Ina Coburger

Scientist Protein Analytics

Navigo Precision

13:40

Ligand development based on platform examples

Hong Hoi Ting

Co-founder & Non-executive Director

NanoMab Technology

14:20

Single-domain antibodies (sdAbs / VHHs / nanobodies): a good targeting tool in RDCs and ADCs

Michal Zimmermann

Associate Director, *In Vitro* Target Validation

AstraZeneca

15:00

Mechanistic strategies for radioconjugate combinations

Moderator: **Hong Hoi Ting**

Participants: **Michal Zimmermann, Ina**

Coburger, Munir Ghesani, Vicki Jardine

15:40

Panel discussion

Choosing the right target, ligand, isotope and combination approach

16:30 - 17:00 Wrap-up & Closing remarks

20:00 Dinner @ "The Ugly Duckling" traditional restaurant

Workshop day 4

Friday 16 October



6th Annual
BIOEMTECH
Preclinical
Workshop

09:30 Registration and welcome coffee

Session 5: Regulatory readiness and late translational decision-making

Jeff Norenberg

Founder, CEO & Chairman

iSeek Biopharma

10:00

How to prepare an IND package for authorities

Vicki Jardine

VP Global Clinical Development

Ratio Therapeutics

10:40

Clinical translation: the biotech perspective

11:20 - 12:00 Coffee break

Moderator: **Jeff Norenberg**

Participants: **Vicki Jardine, Anneli Savinainen**

12:00

Panel discussion

Aligning scientific rationale, regulatory package, hospital feasibility and clinical trial execution

BIOEMTECH

12:40

Closing remarks

14:00 Lunch and Closing Ceremony

Our Speakers & Panelists



6th Annual
BIOEMTECH
Preclinical
Workshop

- **Anneli Savinainen**, VP Head of Preclinical Development **Mariana Oncology (a Novartis company)**



Accomplished biopharmaceutical executive with deep expertise in preclinical research and development, Anneli Savinainen leads the advancement of innovative therapies from discovery through IND-enabling studies into early clinical development. As Vice President and Head of Preclinical Development at Mariana Oncology (a Novartis company), she directs multidisciplinary teams spanning pharmacology, toxicology, DMPK/ADME, and imaging, with a particular focus on precision radioligand therapies (RLTs). She has a strong track record of successful IND submissions across diverse modalities, including targeted oncology programs. Anneli has held leadership and scientific roles at Mariana Oncology, Aura Biosciences, Syros Pharmaceuticals, Shire, EMD Serono, Resolvix Pharmaceuticals, Millennium Pharmaceuticals, and AstraZeneca. She holds a Master of Science in Pharmacology and a Graduate Certificate in Clinical Trial Design and Project Management from Northeastern University, and a Bachelor of Science in Medical Laboratory Sciences from the University of Gothenburg. She is known for building high-performing teams, driving cross-functional collaboration, and delivering high-quality data to enable clinical success.

- **Marion Malenge**, Director RLT Discovery and Preclinical Sciences **Actithera**



Marion is a researcher with over a decade of experience in radiopharmaceutical drug development. Currently, she serves as the Director of RLT Discovery & Preclinical Sciences at Actithera, where she leads the advancement of preclinical radioligand therapy programs from early discovery through translational development.

She holds a PhD in Medicine and Health Sciences from the University of Oslo, with a research focus on the preclinical development of radioimmunotherapies. Her former industry experience includes leadership and scientific roles at ARTBIO, Oncinvent, and Nordic Nanovector, where she contributed to advancing innovative RLT programs toward clinical translation.

Our Speakers & Panelists



6th Annual
BIOEMTECH
Preclinical
Workshop

- **Jon Archbold**, Associate Director, Translational Imaging **Bayer**



Jon Archbold is a translational research scientist with over 15 years of experience spanning several therapeutic areas, applying preclinical imaging to support drug development. He completed his undergraduate studies in neuroscience at Northeastern University and graduate studies in neuroscience at Boston University, where he utilized PET/CT, MRI and autoradiography to characterize the neurodegenerative phenotype of a mouse model of Alzheimer's disease.

Jon currently serves as an imaging lead within the oncology translational sciences organization at Bayer focusing on translating preclinical imaging strategies into clinical applications. Prior to Bayer, Jon was lead study director at Invicro (now Perceptive) in San Diego, working with numerous sponsors to design, execute and deliver preclinical studies assessing PK/PD, biodistribution and efficacy. Before Invicro, Jon spent 8 years at Biogen within the preclinical imaging and pharmacology group, leveraging PET/CT, SPECT/CT, MRI and a range of in vitro/ex vivo techniques to advance drug candidates across the portfolio. Earlier in his career, he worked in a preclinical neuroimaging laboratory during his undergraduate studies and within the preclinical imaging group at Millennium Pharmaceuticals (now Takeda).

- **Elisa Napoli**, Radiopharmaceutical Expert **University of Oslo**



Elisa Napoli is a nuclear physicist currently holding the position of Senior nuclear propulsion researcher at DNV in Norway, where she dedicates to the development of classification rules for nuclear propelled ships. Elisa has a strong expertise in "hands-on" radiochemistry, pre-clinical studies, radiation safety, nuclear metrology and analytical method development for quality control of radiopharmaceuticals, and in general of alpha-, beta- and gamma- emitting radioactive open sources.

Her background combines industry, research, and regulatory experience acquired across leading organizations such as Bayer, the National Institute of Standards and Technology in the USA, and others. Elisa has also conducted experimental research, including pre-clinical studies, and has published several peer-reviewed papers in metrology radioactivity standardization.

She holds a PhD from the University of Oslo, supported by degrees in physics, and is an active contributor to international conferences and collaborations in her field.

Our Speakers & Panelists



6th Annual
BIOEMTECH
Preclinical
Workshop

- **Jon Goodwin**, Director, Discovery **ARTBIO**



At ARTBIO, Jon leads a discovery group encompassing radiobiology and *in vivo* sciences, with the goal of developing small molecules and peptides as optimal targeting ligands for the isotope Lead-212. As a classically trained cell biologist, Jon has 10 years of drug discovery experience, focusing on innovative approaches to first-in-class targets across autophagy, immuno-oncology and neurodegeneration.

- **Famke Van Renesse-Brouwer**, Senior Business-to-Science Manager **TRACER**



With an educational background in Biomedical Sciences and Business administration, she bridges the gap between science and business. After completing her master thesis at the radiopharmacies of GE HealthCare, she continued her career in the radiopharmaceutical field with TRACER as Business to Science manager. TRACER is a dutch clinical research organization (CRO) specializing in first-in-human, phase 0 imaging clinical trials, both for diagnostics and therapeutics. These trials use nuclear and optical molecular imaging techniques to provide critical insights into drug efficiency and enable faster, more accurate decision-making in early drug development. Within TRACER, she maintains a broad network of clinical sites and strategic partners across Europe, including contractual negotiations and clinical site start-ups. In addition, she coordinates clinical translation from tracer development to GMP implementation of radiopharmaceuticals for FIH studies.

- **Munir Ghesani**, Chief Medical Officer **United Theranostics**



Munir Ghesani, MD, FACNM, FACR, FSNMMI, is Chief Medical Officer of United Theranostics and Medical Director of United Theranostics at Princeton. He also serves as an Associate Professor of Neurosurgery and an Adjunct Professor of Radiology at the Icahn School of Medicine at Mount Sinai, where he previously served as Chief of Nuclear Medicine.

With more than 25 years of experience, he has worked extensively across clinical practice, research, clinical trials, and education in nuclear medicine, molecular imaging, and targeted radiopharmaceutical therapy. His interests include PET/CT and SPECT/CT imaging, theranostics, dosimetry, and current and emerging applications of radiopharmaceutical therapies.

Dr. Ghesani is a Past President of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a former Chair of the American Board of Nuclear Medicine and has held several other national leadership roles in nuclear medicine and radiology. He has contributed to over 200 publications and delivered more than 250 presentations at regional, national and international meetings.

Our Speakers & Panelists



6th Annual
BIOEMTECH
Preclinical
Workshop

- **Jan Lennart von Hacht**, Project & Alliance Manager **3B Pharmaceuticals**



Dr. Jan Lennart von Hacht is Project and Alliance Manager at 3B Pharmaceuticals (Berlin, Germany), where he has worked since 2020 in the development of radiopharmaceuticals. He specialises in dosimetry and the quantitative analysis of PET/CT and SPECT/CT imaging data across preclinical and clinical studies, and serves as the central point of contact for external collaborations and the management of clinical sites in investigator-initiated trials (IITs). Previously, he worked as a Project Manager at Parexel Medical Imaging. Before that, as a postdoctoral researcher and PhD student at Charité – Universitätsmedizin Berlin, he focused on GPCR tumor targeting and preclinical imaging with ^{68}Ga PET/CT.

- **Levente Meszaros**, VP Preclinical & Translational Sciences **Radiopharm Theranostics**



After completing his PhD in Imaging Sciences and Radiation Biology at King's College London, Levente worked as a postdoctoral fellow supporting first-in-human diagnostic trials. Later, he joined multiple spin-out companies working in or supporting radiopharmaceutical development. In 2018 he joined NanoMab Technology Limited first in Shanghai then in London, overseeing preclinical, CMC activities and technology transfer supporting two early phase 1 diagnostic trials in China and Germany. Upon returning to London, he contributed to regulatory submissions and execution of a phase 2 diagnostic trial. Following the acquisition of NanoMab's assets, Levente joined Radiopharm Theranostics (RAD) in September 2021 and continues to work there, currently as Vice President, Preclinical and Translational Science. At RAD, he oversees preclinical and R&D activities and coordinates R&D work at Radiopharm Ventures, a joint venture with the MD Anderson Cancer Center. RAD currently has six active clinical trials in the USA and Australia.

- **Ina Coburger**, Team Leader & Senior Scientist Protein Analytics **Navigo Precision**



Ina Coburger, PhD, is a Team Leader & Senior Scientist in Protein Analytics at Navigo Proteins GmbH, Germany, where she works on the purification and characterization of engineered protein candidates for targeted radiotheranostic applications in oncology. She studied Biochemistry and Molecular Biology at Friedrich Schiller University Jena and received her doctorate in Biochemistry there in 2015. Before joining Navigo Proteins in 2021, she held research positions at Friedrich Schiller University Jena and the Fritz Lipmann Institute, where her work encompassed ion channel biology, amyloid precursor protein research, and protein crystallography. Her scientific background in protein purification, biophysical characterization, and structure-function analysis now supports the development of highly specific protein-based approaches for next-generation radioligand therapies.

Our Speakers & Panelists



6th Annual
BIOEMTECH
Preclinical
Workshop

- **Hong Hoi Ting**, Co-founder & Non-executive Director **NanoMab Technology**



Ting is biochemist and entrepreneur. He is founder of NanoMab Technology which uses the single domain antibody (nanobody) platform to generate cancer biomarker specific-sdAbs for theranostic radiopharmaceuticals. NanoMab has licensed five of its products to three different licensees and two of these products are now in human clinical trials. He is also co-founder and current board member of Full-Life Technology - a fully integrated radiopharmaceutical company with R&D based in Shanghai and a radioisotope and radiopharmaceutical manufacturing site based in Belgium. His current interests involve using AI to support the modification of different target specific vectors to increase their efficacies.

- **Michal Zimmermann**, Associate Director, *In Vitro* Target Validation **AstraZeneca**



Michal is a cancer biologist with 10+ years of academic and industry experience interrogating mechanisms that shape anti-tumor therapeutic activity. He is an Associate Director in Radioconjugate Discovery at AstraZeneca, leading a team that designs rational drug combinations with targeted radiopharmaceuticals. His work integrates mechanistic biology to inform novel combination hypotheses, optimized dosing strategies, and translational assay development.

Previously, Michal was Director of Cancer Biology at Repare Therapeutics, a precision oncology company advancing synthetic lethality. He helped develop combination strategies for multiple clinical DNA damage response inhibitor programs.

Michal completed graduate research as a visiting student at The Rockefeller University, earned a PhD from Masaryk University (Czech Republic), and undertook postdoctoral training at the Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital (Toronto, Canada).

Our Speakers & Panelists



6th Annual
BIOEMTECH
Preclinical
Workshop

- **Jeff Norenberg**, Founder, CEO & Chairman **iSeek Biopharma**



Jeffrey P. Norenberg, PharmD, PhD, is Founder, Chairman, and Chief Executive Officer of iSeek Biopharma, where he works with a multidisciplinary team developing precision molecular imaging drugs and radioligand therapies. The company's lead program, LEUKOPET™ [^{64}Cu]IS1051, entered the CLEARVIEW Phase 1 first-in-human study in August 2026.

Over nearly four decades, Jeff has worked across academia, nuclear pharmacy, biotechnology, regulatory science, and radiopharmaceutical translation. He has served as Principal Investigator or Co-Principal Investigator for 13 first-in-human clinical trials and has practical experience navigating the scientific, regulatory, manufacturing, and supply-chain challenges involved in moving new radiopharmaceuticals from preclinical studies into patients.

Jeff is Professor Emeritus of Pharmacy and Medicine at the University of New Mexico. He has authored or co-authored more than 150 peer-reviewed publications, holds 11 issued U.S. patents, and is a Fellow of ASHP, APhA, ACNM, and SNMMI. At the BIOEMTECH 6th Preclinical Workshop, he will share practical lessons and perspectives on translating promising radiopharmaceutical programs into clinical development.

- **Vicki Jardine**, VP Global Clinical Development **Ratio Therapeutics**



Vicki Jardine is Vice President, Global Clinical Development at Ratio Therapeutics, and has more than 16 years of experience leading oncology drug development programs from first-in-human studies through pivotal Phase 3 trials. She has particular interest in the development of novel radiopharmaceutical therapies and currently oversees Clinical Development for several innovative programs at Ratio including both therapeutic and diagnostic agents. Previously, Vicki held leadership roles in radiopharmaceutical therapy development at ARTBIO, where she built the clinical development function for a ^{212}Pb radioligand platform, and at Bayer, where she led early-phase clinical development programs for multiple targeted alpha radiotherapeutic agents utilizing ^{227}Th and ^{225}Ac .

Vicki completed her medical doctorate, bachelor's degree in Neuroscience, and Ph.D. in Radiology at the University of Cambridge and Addenbrooke's Hospital, UK. She has served as clinical lead for global regulatory interactions across the FDA, EMA, and MHRA, and contributed to cross-industry working groups and literature focused on radiopharmaceutical therapy clinical development.

Notes




6th Annual
BIOEMTECH
Preclinical
Workshop



Be part of our Workshop

 **BIOEMTECH**




6th Annual **BIOEMTECH** Preclinical Workshop

Rates:

- **€ 950 Early bird**
(registrations before July 20, 2026)
- **€1150 Regular**
(registrations after July 20, 2026)
- **€780 Student**

Register now!



Venue

Central Athens Hotel

21 Apollonos str., 10557, Athens

**Hands-On Session will be held at
BIOEMTECH Laboratories**

271 Kleisthenous str., 15344, Gerakas

**See you soon in Athens
for four days of science
and networking!**